Both acute treatments with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin and sGC activator showed antioxidant and anti-inflammatory properties when the myocardium of HF and HFpEF patients and rats were treated (Kolijn et al. 2020b). This evidence concerns the gene SLC5A2 and hydrops fetalis.